Clonal haematopoiesis and cardiovascular disease, defining risk, filling gaps, and framing the future
Alec P. Morley, Paul Carter, Rupen Hargreaves, Dorina-Gabriela Condurache, Michael Anderson, Sean Wen, Zahra Raisi-Estabragh · 2026
Read Clonal haematopoiesis and cardiovascular disease, defining risk, filling gaps, and framing the future by Alec P. Morley, Paul Carter, Rupen Hargreaves, Dorina-Gabriela Condurache, Michael Anderson, Sean Wen, Zahra Raisi-Estabragh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13230803.txt.
Description
Alec Morley and co-authors review clonal haematopoiesis as a newly seen driver of heart disease in this 2026 paper. The condition means one blood stem cell line has expanded in the body. It is common in older people and involves no blood cancer. Recent evidence ties it to higher rates of heart and vessel disease. The review covers blocked arteries, heart failure, and rhythm faults. Links with cancer care are also examined.
Mutation type and clone size may change the risk a person carries. The authors point out biases that color the current literature. Gaps in knowledge are named plainly in the title's terms. Clinical fallout includes who might merit closer heart checks. The paper frames where the field should go next. It is a review, pooling many groups' findings. Their aim is to define risk properly before clinics act.
Catalog record
| CREATOR | Alec P. Morley, Paul Carter, Rupen Hargreaves, Dorina-Gabriela Condurache, Michael Anderson, Sean Wen, Zahra Raisi-Estabragh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 89 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |